Mark Frohlich, M.D., joined Dendreon in 2005 and was promoted to the position of senior vice president of clinical affairs and chief medical officer in 2007. He previously oversaw medical affairs at Xcyte Therapies. Prior to that was an assistant professor in the Division of Hematology/Oncology at the University of California, San Francisco, where he specialized in urologic oncology and was active in laboratory, translational and clinical research. Dr. Frohlich received his M.D. from Harvard Medical School and did his post doctoral training in oncology at the University of California, San Francisco. He also has a B.S. from Yale in electrical engineering and economics.